Background
Ending the HIV epidemic by 2030 remains a prime global objective. Pre-exposure prophylaxis (PrEP): dapivirine vaginal ring (ring PrEP), Tenofovir disoproxil fumarate-based oral PrEP (oral PrEP) and long-acting injectable PrEP (LA PrEP) offer substantial reductions in HIV transmission when adherence and retention are satisfactory. Using local epidemiological, programmatic, and cost data, we determined the cost-effectiveness of alternative PrEP scale-up scenarios in Eswatini.
Methods
We simulated scale-up scenarios for LA PrEP, oral PrEP, and ring PrEP, and a “choice based PrEP” option where individuals select their preferred modality. Each modality was simulated at varying coverage (10%, 50%, and 70%) targeting populations at increased risk of HIV acquisition: (adolescent girls and young women 15-24 years[AGYW], adolescent boys and young men 15-23 years[ABYM], males aged 24–35, female sex workers [FSW], men who have sex with men [MSM], and people with any condition of alcohol, substance and mood disorder (CASM). Additionally, we assessed the effect of choice-based PrEP, modeled at the same coverage levels, and with approximately 75% of people preferring LA PreP over other modalities. Outcomes included infections averted, additional quality-adjusted life years (QALYs) gained, cost per infection averted and cost per QALY gained through 2030. We conducted sensitivity analyses to assess outcome robustness against different levels of willingness-to-pay for health benefits.
Results
Targeting FSW with LA PrEP was the most cost-effective strategy, projected to avert 200-1,500 additional infections through 2030 at an incremental cost-effective ratio (ICERs) of US$2,293 per infection averted and US$3,275–US$3,675 per QALY gained. Sequentially targeting MSM and AGYW With LA PrEP averted 1,541 and 5,200 additional infections at ICERs US$13,220 and US$19,418 per QALY gained, respectively. Expanding PrEP coverage to all populations averted more infections (9,623) but at higher cost (US$69,041 per infection averted.
Targeting FSW with LA-PrEP coverage at 50% compared to choice based PrEP modality, increased the ICER per QALY gained from US$3,675 to US$4,917.
Conclusions
Scaling up LA PrEP and/or choice-based PrEP were the most cost-effective strategies. Our analysis underscores the potential role of LA PrEP as a high value strategic tool in HIV infection prevention.